New Assessment System in Measuring Symptom Distress in Cancer Patients (NCT00505245) | Clinical Trial Compass
RecruitingNot Applicable
New Assessment System in Measuring Symptom Distress in Cancer Patients
United States6,500 participantsStarted 1999-04-13
Plain-language summary
This trial studies how well a new assessment system (MDASI or other MD Anderson-developed PRO instrument) works in measuring symptoms and the impact on quality of life in cancer patients. Development of a new assessment system may provide more information about the common symptoms that may occur in patients due to cancer and its treatment and how the symptoms impact quality of life.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* NORMAL SAMPLES: Community dwelling adults 18 years of age or older
* PATIENT SAMPLES: Inpatients and outpatients 18 years of age or older, being followed at UT MD Anderson
* EXPERT PANEL PROFESSIONAL PARTICIPANTS: Physician or other healthcare provider with at least 5 years of experience caring for patients with the disease and/or treatment of interest, at least one publication in the last 5 years dealing with the disease and/or treatment of interest (physician only), ability to speak and read English, consent to participate
* EXPERT PANEL FAMILY CAREGIVERS PARTICIPANTS: Identification as a family caregiver by patient enrolled as expert panel participant with the disease and/or treatment of interest, 18 years of age or older, ability to speak and read English, consent to participate
* EXPERT PANEL PATIENT PARTICIPANTS: Patient with identified family caregiver participating on Expert Panel, willingness to receive packet for expert panel participation
Exclusion Criteria:
* EXPERT PANEL PATIENT PARTICIPANTS: Patient with identified family caregiver participating on expert panel, willingness to receive packet for expert panel participation
What they're measuring
1
MD Anderson Symptom Inventory (MDASI) tool or other MD Anderson-developed patient reported outcome (PRO) instrument validity
Timeframe: Up to 21 years
2
MD Anderson Symptom Inventory (MDASI) tool or other MD Anderson-developed PRO instrument reliability.
Timeframe: Up to 21 years
3
MD Anderson Symptom Inventory
Timeframe: Baseline up to 21 years
4
Eastern Cooperative Oncology Group Functional Status scale
Timeframe: Baseline up to 21 years
5
EuroQOL 5 Dimensions questionnaire
Timeframe: Baseline up to 21 years
6
The change in the symptom severity and interference with the function
Timeframe: Baseline up to 21 years
7
MD Anderson Symptom Inventory (MDASI) tool or other MD Anderson-developed PRO instrument sensitivity
Timeframe: Up to 21 years
8
The quality of life questionnaire will be assessed.